Applies to: Renal DysfunctionThe safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis. Monitor these patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis flare or HBV reactivation.Moderate Potential Hazard, Moderate plausibility.

On eHealthMe, you can check real-world data from 16 million patients, and personalize the results to your gender and age.
Increased levels can lead to new or more severe side effects. Select one or more newsletters to continue. The study is created by eHealthMe based on reports of 47 people who take Epclusa and Multivitamin from the FDA, and is updated regularly. Sofosbuvir and velpatasvir are substrates of drug transporters P-gp and BCRP while GS-331007 (the predominant circulating metabolite of sofosbuvir) is not; In vitro, slow metabolic turnover of …

Do not start, stop, or change the dosage of any medicine before checking with them first.Selected from data included with permission and copyrighted by First Databank, Inc. No dosage recommendation can be given for patients with severe renal impairment or ESRD. www.covid19-druginteractions.org - a new website for drug interactions with experimental agents used to treat COVID-19. This information is generalized and not intended as specific medical advice.

This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. doctor or pharmacist) for more information.One of your hepatitis C medicines may increase the amount of rosuvastatin your body absorbs.The amount of rosuvastatin in your blood may increase and cause harmful effects.Make sure your healthcare professionals (e.g. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.Severe. Drug interaction overview.

This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.Things to remember when you fill your prescription.WebMD does not provide medical advice, diagnosis or treatment. Drugs affecting sofosbuvir/velpatasvir. Applies to: Liver Disease, CirrhosisSofosbuvir is extensively metabolized in the liver.

On Jun, 13, 2020. Applies to: Immunodeficiency, Infectious HepatitisDirect-acting antiviral agents against the hepatitis C virus, alone or in combination with other hepatitis C virus (HCV) direct acting antiviral therapies have been associated with hepatitis B reactivation in HCV/HBV coinfected patients who were undergoing or had completed treatment with these agents, and who were not receiving HBV antiviral therapy. A series of mini-lectures on topics including pharmacology, hepatitis and drug-drug interactions Prescribing Resources.

Epclusa sofosbuvir 400 mg / velpatasvir 100 mg (GSI 7916) Start now, it's free . Contact your healthcare professional (e.g.

Decreased levels may mean that the drug won’t be as effective. No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).Moderate Potential Hazard, Moderate plausibility.